Wuxi Biologics (2269 HK): Lowered 2023 Revenue Expectation Amid Challenging Industry Outlook
Wuxi Biologics expects 2023 revenue will miss by $400M due to reduced number of projects amid industry slowdown. New capacity ramp up, together...
434 Views
ECM Weekly (5th Nov 2023)- Midea, WuxiXDC, Cello, Honasa, Qyuns, Ecopro, Lalatech, Mankind, TWE, VNT
Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
391 Views
Wuxi Biologics (2269.HK) 23H1 - The Positives, the Negatives and the Outlook
There're highlights in WuXi Bio’s interim report, making us look forward to its full-year result. But WuXi Bio faces challenges in order...
400 Views
WuXi Biologics (2269 HK) – Impressive post-pandemic performance
1H23 revenue impressively beat its previous guidance of low-teens growth, mainly attributable to the strong 59.7% YoY growth of non-COVID revenue.
354 Views
Wuxi Biologics (2269 HK): Mixed 1H23 Result; Strong Non-COVID Business Momentum Enhances Visibility
In 1H23, revenue grew 18% YoY to RMB8.5B, while non-COVID revenue increased 60% YoY. Total backlog grew 9% YoY to $20B. Backlog within three years...
492 Views